Get the latest market trends in your inbox
Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Mallinckrodt offices in New Jersey. Photo: Salwan Georges/The Washington Post via Getty Images
Mallinckrodt is floating a $1.6 billion proposal to settle allegations that it fueled the opioid crisis by pushing its painkillers. The drug company would make payments in the eight years after its generics business, which sells oxycodone and hydrocodone pills, emerges from bankruptcy.
Why it matters: The attorneys general from 47 states and territories, as well as the plaintiffs in the global opioid lawsuit, are supporting the deal, Mallinckrodt said. Mallinckrodt's brand-name drug business will not be affected, but its generics bankruptcy marks the third opioids bankruptcy, after Purdue Pharma and Insys Therapeutics.